Rituximab

monoclonal antibody

Identifier: CI-DRUG-00000703
Entity page: /drug/rituximab ↗
Edges: 1,671

Neighbours: 21 cancers1 genes10 trials15 approvals
Drawn: 47 of 47 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Rituximab approved for …APPROVED_FOR20 of 35show all (up to 200)
→ approved for	Non-Hodgkin Lymphomahematologic_malignancy	supports	FDA ORIG	Non-Hodgkin Lymphoma	1	Regulatory	openfda	graph →
→ approved for	Non-Hodgkin Lymphomahematologic_malignancy

→ approved for

EMA · EU · 2020Ruxience is indicated in adults for the following indications: Non?Hodgkin’s lymphoma (NHL) Ruxience is indicated for the treatment of previously untreated patients with stage III?IV follicular lymphoma in combination with chemotherapy. Ruxience maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. Ruxience monotherapy is indicated for treatment of patients with stage III?IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. Ruxience is indicated for the treatment of patients with CD20 positive diffuse large B cell non?Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. Chronic lymphocytic leukaemia (CLL) Ruxience in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy. Rheumatoid arthritis Ruxience in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease?modifying anti?rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies. Ruxience has been shown to reduce the rate of progression of joint damage as measured by X?ray and to improve physical function, when given in combination with methotrexate. Granulomatosis with polyangiitis and microscopic polyangiitis Ruxience, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA). Pemphigus vulgaris Ruxience is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).

EMA (EU) · approved · 2020-04-01 · Ruxience is indicated in adults for the following indications: Non?Hodgkin’s lymphoma (NHL) Ruxience is indicated for the treatment of prev…

—

approved

not mapped

Regulatory

ema

open ↗

Rituximab targets …TARGETS1 of 1
→ targets	MS4A1	—	BINDING AGENT	—	1	Curated	chembl	graph →

Rituximab investigated for …INVESTIGATED_FOR15 of 43show all (up to 200)
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Acute Lymphoblastic Leukemiahematologic_malignancy	unknown	4	Acute Lymphoblastic Leukemia	1	Curated	chembl	graph →
→ investigated for	Chronic Lymphocytic Leukemiahematologic_malignancy	unknown	4	Chronic Lymphocytic Leukemia	1	Curated	chembl	graph →
→ investigated for	Non-Hodgkin Lymphomahematologic_malignancy	unknown	4	Non-Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Waldenstrom Macroglobulinemiahematologic_malignancy	unknown	3	Waldenstrom Macroglobulinemia	1	Curated	chembl	graph →
→ investigated for	Lymphoid Leukemiahematologic_malignancy	unknown	3	Lymphoid Leukemia	1	Curated	chembl	graph →
→ investigated for	Burkitt Lymphomahematologic_malignancy	unknown	3	Burkitt Lymphoma	1	Curated	chembl	graph →
→ investigated for	Leukemiacancer_family	unknown	3	Leukemia	1	Curated	chembl	graph →
→ investigated for	Mantle Cell Lymphomahematologic_malignancy	unknown	3	Mantle Cell Lymphoma	1	Curated	chembl	graph →
→ investigated for	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissuehematologic_malignancy	unknown	3	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	1	Curated	chembl	graph →
→ investigated for	Follicular Lymphomahematologic_malignancy	unknown	3	Follicular Lymphoma	1	Curated	chembl	graph →
→ investigated for	Lymphomacancer_family	unknown	3	Lymphoma	1	Curated	chembl	graph →
→ investigated for	Hodgkin Lymphomahematologic_malignancy	unknown	3	Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Blastic Plasmacytoid Dendritic Cell Neoplasmhematologic_malignancy	unknown	2	Blastic Plasmacytoid Dendritic Cell Neoplasm	1	Curated	chembl	graph →
→ investigated for	B-Cell Malignant Neoplasmcancer_family	unknown	2	B-Cell Malignant Neoplasm	1	Curated	chembl	graph →

Rituximab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 208show all (up to 200)
→ investigated in trials for	Lymphomacancer_family 324 trials (26 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	324	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Large B-Cell Lymphoma 191 trials (58 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Large B-Cell Lymphoma	191	Observed	clinicaltrials	graph →
→ investigated in trials for	Non-Hodgkin Lymphomahematologic_malignancy 183 trials (21 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Non-Hodgkin Lymphoma	183	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemiahematologic_malignancy 151 trials (30 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia	151	Observed	clinicaltrials	graph →
→ investigated in trials for	Mantle Cell Lymphomahematologic_malignancy 132 trials (41 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Mantle Cell Lymphoma	132	Observed	clinicaltrials	graph →
→ investigated in trials for	Follicular Lymphomahematologic_malignancy 117 trials (32 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Follicular Lymphoma	117	Observed	clinicaltrials	graph →
→ investigated in trials for	Leukemiacancer_family 98 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	98	Observed	clinicaltrials	graph →
→ investigated in trials for	Small Lymphocytic Lymphoma 85 trials (19 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Small Lymphocytic Lymphoma	85	Observed	clinicaltrials	graph →
→ investigated in trials for	Marginal Zone Lymphoma 74 trials (25 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Marginal Zone Lymphoma	74	Observed	clinicaltrials	graph →
→ investigated in trials for	Waldenstrom Macroglobulinemiahematologic_malignancy 58 trials (10 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Waldenstrom Macroglobulinemia	58	Observed	clinicaltrials	graph →
→ investigated in trials for	B-Cell Malignant Neoplasmcancer_family 46 trials (11 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	B-Cell Malignant Neoplasm	46	Observed	clinicaltrials	graph →
→ investigated in trials for	Grade 1 Follicular Lymphoma 41 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Grade 1 Follicular Lymphoma	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Grade 2 Follicular Lymphoma 39 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Grade 2 Follicular Lymphoma	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissuehematologic_malignancy 36 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Nodal Marginal Zone Lymphoma 34 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Nodal Marginal Zone Lymphoma	34	Observed	clinicaltrials	graph →

Rituximab studied in …STUDIED_INderived10 of 1,384show all (up to 200)
→ studied in	NCT00092222Phase 2 · active not recruiting Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity · 1,384 trials list this drug (337 active)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02180711Phase 1/Phase 2 · active not recruiting Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma · 1,384 trials list this drug (337 active)	—	—	Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03418038Phase 2 · recruiting Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · 1,384 trials list this drug (337 active)	—	—	Lymphoma,Hodgkin Lymphoma,Chronic Myelomonocytic Leukemia+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · 1,384 trials list this drug (337 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05600686Phase 2 · active not recruiting Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma · 1,384 trials list this drug (337 active)	—	—	Double-Expressor Lymphoma,High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements,High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT06350318Phase 2 · recruiting Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas · 1,384 trials list this drug (337 active)	—	—	B-Cell Malignant Neoplasm,Follicular Lymphoma,Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06846671Phase 3 · recruiting A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors · 1,384 trials list this drug (337 active)	—	—	Chronic Lymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT06943872Phase 3 · recruiting A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) · 1,384 trials list this drug (337 active)	—	—	Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04679012Phase 2 · active not recruiting Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation · 1,384 trials list this drug (337 active)	—	—	Chronic Lymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05023980Phase 3 · active not recruiting A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 1,384 trials list this drug (337 active)	—	—	Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths